DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Pulmonary Arterial Hypertension Market is estimated to be USD 8.1 Bn in 2021 and is expected to reach USD 11.68 Bn by 2027, growing at a CAGR of 6.2%.
Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH). Several Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the growth rate of the global pulmonary arterial hypertension market.
However, discontinuing of drug production by major players during clinical trials and stringent regulations by Government, lack of awareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to hinder the market growth. Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.
Growing Burden of Pulmonary Arterial Hypertension
Government and Private Support for the Development of Orphan Drugs
Growing Geriatric Population
Patent Expiration of Key Molecules
Side Effects Associated with the Drugs
Lack of Awareness among People in Developing Countries
High Costs of Diagnosis and Treatment
Lack of Awareness
Expiry of Patents
Advance Oral Drugs for Pulmonary Arterial Hypertension
Technology Advancements such as Biomaker and New Gene Therapy for the Treatment
The Global Pulmonary Arterial Hypertension is segmented based on Drug Class, Route of Administration, Distribution Mode, and Geography.
Global Pulmonary Arterial Hypertension Market, By Drug Class
Prostacyclin and Prostacyclin Analogs
Soluble Guanylate Cyclase (SGC) Stimulators
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase 5 (Pde-5)
Calcium Channel Blockers
Global Pulmonary Arterial Hypertension Market, By Route of Administration
Global Pulmonary Arterial Hypertension Market, By Distribution Mode
Global Pulmonary Arterial Hypertension Market, By Geography
The Middle East and Africa
Gilead Sciences, Inc.
United Therapeutics Corporation
Novartis International AG
GlaxoSmithKline Plc. (GSK)
Dong-A ST Co., Ltd.
Merck Sharp & Dohme Corp.
Bayer HealthCare AG
Actelion Pharmaceuticals Ltd
Daiichi Sankyo Company, Limited
Johnson & Johnson
Bristol-Myers Squibb Company
Why buy this report?
The report offers a comprehensive evaluation of the Global Pulmonary Arterial Hypertension Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
The report also contains the competitive analysis using the Competitive Quadrant, the publisher's Proprietary competitive positioning tool.
For more information about this report visit https://www.researchandmarkets.com/r/6b7u5l
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005220/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900